The 1,3,4-oxadiazole is a compact five-membered ring containing two nitrogen atoms and one oxygen atom, and it has long been a favourite building block in medicinal chemistry because it appears in compounds with antibacterial, antifungal, anti-inflammatory and anticancer activity. The researchers, led by Rekha Singh and Jagadish Singh of Guru Ghasidas Vishwavidyalaya in Bilaspur, together with Balaji Wamanrao Matore and colleagues, drew on two decades of their own prior work with this scaffold. Their design strategy placed a phenyl ring directly on the oxadiazole core, a motif also found in the approved drug zibotentan, and attached a second chlorinated phenyl ring through an imine, or CH=N, linker at the five-position of the ring.

Synthesis proceeded in three straightforward steps. Substituted aldehydes were first condensed with semicarbazide hydrochloride in ethanol to form Schiff base intermediates, which were then cyclised with iodine and potassium carbonate in 1,4-dioxane at 80 degrees Celsius to build the oxadiazole ring. A final condensation with different chloro-substituted aldehydes delivered the nine target compounds, R1 through R9, in yields above 90 percent. Every product was confirmed by FT-IR, proton NMR and mass spectrometry, with the diagnostic imine proton appearing between 8.73 and 8.99 parts per million in the NMR spectra, and melting points recorded for each purified solid.

Before any wet-lab testing, the team ran a battery of computational experiments. Density functional theory calculations using the DMol3 code suggested that all nine compounds are more chemically reactive than the kinase inhibitor sorafenib, with R3, R4 and R6 showing the smallest HOMO-LUMO gaps at 0.086 Hartree, a measure that correlates with a molecule’s willingness to engage in electronic interactions. Target prediction servers, including PASS and SwissTargetPrediction, then pointed the researchers toward kinase receptors, a family of enzymes heavily implicated in breast cancer biology through receptors such as VEGFR2, EGFR, PDGFR and HER2.

VEGFR2, the vascular endothelial growth factor receptor 2, emerged as the priority target because of its central role in angiogenesis, the process by which tumours recruit new blood vessels to fuel their growth and spread. Blocking VEGFR2 is a clinically validated strategy in breast cancer management, and the researchers selected the crystal structure 4ASD from the Protein Data Bank for docking studies. After validating their protocol by re-docking the co-crystallised ligand and achieving root-mean-square deviations well below the accepted two angstrom threshold, they docked all nine compounds into the ATP binding pocket using three independent algorithms: CDOCKER, LibDock and AutoDock Vina.

The docking results told a remarkably consistent story. Compound R3 achieved the highest CDOCKER interaction energy at 41.54 and the best LibDock score at 130.38, and it formed fifteen separate contacts with the protein, including hydrogen bonds to GLU885, ASP1046 and LYS868, three residues known to stabilise ATP-competitive inhibitors at the hinge region of the kinase. Twelve additional hydrophobic contacts with residues such as LEU840, VAL848, PHE918 and CYS1045 locked the molecule deep in the pocket. Fourteen of these interactions were shared with the co-crystallised reference ligand, meaning R3 essentially mimics the binding mode of a proven VEGFR2 inhibitor. Binding free energy calculations confirmed the picture, with R3 showing the most favourable stability of the series at minus 84.42 kilocalories per mole, compared with minus 142.01 for sorafenib.

Structure-activity relationship analysis revealed the decisive role of chlorine positioning. Derivatives bearing meta and para chloro substituents on their phenyl rings, compounds R1 through R4, consistently outperformed those with ortho substitution, compounds R5 through R9. The explanation is steric: an ortho chlorine crowds the space near the imine linker and prevents the molecule from adopting the flat, extended conformation needed to slot into the VEGFR2 pocket. The ortho-substituted compounds formed almost no favourable interactions in docking, showed weaker binding free energies, and translated this deficit directly into higher IC50 values in the cell assays. It is a textbook example of how a single atom, moved a few angstroms, can flip a molecule from active to inert.

The computational predictions were then put to the test in the laboratory. Using the MTT assay against MCF-7 breast cancer cells at concentrations ranging from 5 to 80 micromolar, all nine compounds showed moderate to potent, concentration-dependent cytotoxicity, with IC50 values spanning 8.068 to 17.343 micromolar. Three compounds, R1, R3 and R4, fell below the 10 micromolar threshold, and R3 led the series at 8.068 micromolar, close to the 4.051 micromolar recorded for doxorubicin under the same conditions. Microscopy of treated cultures showed reduced cell density and altered morphology relative to untreated controls, consistent with the viability data.

Pharmacokinetic modelling added a further layer of optimism. SwissADME predictions indicated high gastrointestinal absorption and good oral bioavailability for the whole series, with moderate lipophilicity, LogP values of 3.3 to 3.5, and a low topological polar surface area of 51.28 square angstroms, a balance well suited to membrane permeability. The ProTox-II server classified all compounds in toxicity class 4 with an LD50 of 375 milligrams per kilogram and predicted them to be non-carcinogenic, non-mutagenic and non-immunotoxic, although moderate hepatotoxicity was flagged for the series, mirroring the profile of sorafenib itself. The authors note two caveats for future optimisation: moderate aqueous solubility may complicate formulation, and the predicted ability to cross the blood-brain barrier raises the possibility of off-target central nervous system exposure that must be managed in an anticancer context.

The study’s authors are careful to frame the work as an early-stage screening effort. MCF-7 served as the initial model, and broader evaluation across additional cancer cell lines and normal cell models will be needed to establish selectivity and safety, particularly for R3, which the team identifies as the lead candidate for further development. Even so, the internal consistency of the data is compelling: the same substitution pattern that produced the best docking scores also produced the strongest binding free energies and the lowest IC50 values, and the key residues engaged by R3 match those exploited by clinically approved VEGFR2 inhibitors such as sorafenib. For a scaffold as chemically accessible as the 1,3,4-oxadiazole, synthesised in three steps from cheap starting materials with yields above 90 percent, that combination of potency, predictability and synthetic simplicity makes R3 a lead worth watching as VEGFR2-targeted breast cancer drug discovery moves forward.

Subject of Research: Design and evaluation of 1,3,4-oxadiazole derivatives as VEGFR2-targeted anticancer agents against breast cancer

Article Title: Design, synthesis, SAR, in silico and in vitro evaluation of 1, 3, 4-oxadiazole derivatives against breast cancer

Article References: Singh, R., Matore, B. W., Murmu, A., Lakra, N., Banjare, P., Namdeo, K. P., Roy, P. P., & Singh, J. (2026). Design, synthesis, SAR, in silico and in vitro evaluation of 1, 3, 4-oxadiazole derivatives against breast cancer. Discover Chemistry, 3(1), Article 539. https://doi.org/10.1007/s44371-026-00898-w

Image Credits: AI Generated

DOI: 10.1007/s44371-026-00898-w

Keywords: breast cancer, 1,3,4-oxadiazole, VEGFR2, MCF-7, molecular docking, structure-activity relationship, ADMET, drug discovery, angiogenesis, kinase inhibitors, MTT assay, medicinal chemistry